One of the most promising areas of cancer research and treatment is known as immunotherapy, in which a patient’s own immune system is enlisted in the fight against cancer. This approach is more than just a narrow field of study at City of Hope. It is the central component of groundbreaking research and clinical trials currently underway.
City of Hope continues to be at the forefront of a powerful form of immunotherapy known as chimeric antigen receptor (CAR) T cell therapy. Using this approach, immune cells are taken from a patient’s bloodstream, reprogrammed to recognize and attack a specific protein found in cancer cells, then reintroduced into the patient’s system, where they get to work destroying targeted tumor cells.
City of Hope is leading the way in advancing CAR T therapies by:
Applying our proprietary CAR T technology in active preclinical and clinical programs across a range of hematologic cancers and solid tumors.
Partnering with global biopharmaceutical companies to make their therapies available to patients
Collaborating with other academic researchers to advance clinical research in areas of high unmet medical need